CRT-402 / CREATE Medicines - LARVOL DELTA

A Study to Test CRT-402 in Refractory Autoimmune Disease (clinicaltrials.gov) - P1/2 | N=34 | Not yet recruiting | Sponsor: Myeloid Therapeutics

New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis

CREATE Medicines…announced that it has received Human Research Ethics Committee (HREC) approval in Australia to begin its first-in-human Phase 1/2 clinical trial of CRT-402, CREATE's lead in vivo CAR-T candidate for the treatment of autoimmune diseases (PRNewswire) - "Australian HREC approval clears the initiation of CREATE's first-in-human Phase 1/2 study evaluating CRT-402 in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM). HREC approval represents the final regulatory step required to begin patient enrollment in Australia."

First-in-human • New P1/2 trial • Systemic Lupus Erythematosus • Systemic Sclerosis

CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology (PRNewswire) - "In autoimmune, CREATE's lead program CRT-402, a next generation CD19 targeted in vivo CAR-T therapy, has demonstrated deep and durable B cell depletion in non-human primates, with the potential to enable immune reset through the flexibility of repeat dosing. The company is also advancing a dual CAR CD19 x BCMA directed therapy designed to broaden therapeutic reach across refractory autoimmune indications...In oncology, CREATE continues to advance therapies focused on areas of high unmet need. Early clinical data from the company's MT-303 program in frontline hepatocellular carcinoma has demonstrated an extremely compelling response profile."

Financing • Immunology • Solid Tumor